Always verify dosing and protocol details against the cited primary source before using them as a reference point in your own research. Reconstituting Kisspeptin (a 54-amino acid peptide) for subcutaneous microdosing requires careful solvent selection to prevent aggregation. This article covers pH considerations, dose math, and stability data from published protocols.
What Reconstitution Requires
Kisspeptin is prone to aggregation at neutral pH. Research (Millar 2004) shows that acidic conditions, something like pH 3.5–4.5, keep the peptide monomeric. Three factors matter: 1) solvent pH, 2) peptide concentration, 3) handling temperature.
Bacteriostatic water (pH 5.0–6.5) often causes visible particulates. Dilute acetic acid (0.1% v/v, pH ~3.2) is a common choice. Some protocols use 10 mM sodium acetate buffer (pH 4.0). For microdosing, where final concentrations are low (in the neighbourhood of 50–200 mcg/mL), aggregation risk drops but remains if pH is above 5.0.
Similar challenges exist with other peptides. How to Reconstitute MOTS-c Without Aggregation details pH-dependent aggregation for that mitochondrial peptide. Always filter the reconstituted solution through a 0.22 µm membrane to remove any pre-formed aggregates.
Dose-Math Worked Example from a Published Protocol
A microdosing study (George 2016) used 1.0 nmol/kg subcutaneous Kisspeptin-10. For a 70 kg subject, that is 70 nmol. Kisspeptin-10 has a molecular weight of 1302.5 g/mol. The required mass: 70 nmol × 1302.5 g/mol = 91.2 mcg.
If the vial contains 1 mg of lyophilized powder, reconstitute with 1.0 mL of 0.1% acetic acid to get 1000 mcg/mL. Then dilute further: 0.1 mL of that stock (100 mcg) into 0.9 mL diluent yields 100 mcg/mL. A 0.91 mL injection provides 91 mcg. For smaller doses, adjust the dilution. Always confirm calculations with the primary reference.
Kisspeptin-54, the full-length peptide, has a molecular weight around 5857 Da. Doses in research are often lower, something like 0.3–1.0 nmol/kg. The math scales similarly. Use an analytical balance for weighing if starting from raw powder. For pre-aliquoted vials, assume the stated mass is accurate within ±10%.
Stability Considerations
Kisspeptin in acidic solution is stable for up to 30 days at 4°C (Dhillo 2005). Freeze-thaw cycles accelerate aggregation. Aliquot the stock into single-use vials and store at -20°C. Avoid repeated warming.
Oxidation of methionine residues can occur. Adding 0.1% methionine or using nitrogen-purged vials helps. For microdosing, where syringes may be pre-filled, stability at room temperature matters. Data suggest less than 10% degradation over 24 hours at 25°C when pH is below 4.0.
Peptide adsorption to plastic surfaces is another concern. Low concentrations (below 50 mcg/mL) can lose 20–30% to syringe walls. Using siliconized glass or adding 0.1% bovine serum albumin reduces loss. Always validate recovery in your specific setup.
Common Pitfalls Described in Literature
Three pitfalls appear frequently: 1) using bacteriostatic water without pH adjustment, 2) injecting cold solution causing pain, 3) miscalculating nmol-to-mcg conversions. A 2018 review (Skorupskaite 2018) noted that aggregation can reduce bioavailability by half.
Another issue is confusing Kisspeptin-10 with Kisspeptin-54. The shorter fragment is more potent per mcg but less stable. Verify the peptide identity before reconstitution. Also, some protocols use saline as diluent, but saline has no buffering capacity and pH can drift above 6.0 over time.
Where research is preliminary, this is flagged in the text. Absence of long-term human data should be assumed for most peptides covered here.